Featuring perspectives from Dr Bradley J Monk, Dr David M O’Malley, Ms Kathryn M Schlenker and Ms Jaclyn Shaver, moderated by Dr O’Malley, including the following topics:

• Introduction (00:00)
• Overview of Ovarian Cancer (OC) (2:12)
• Role of PARP Inhibitors in Advanced OC (4:56)
• Current and Potential Future Role of Mirvetuximab Soravtansine in OC (28:45)
• Role of Relacorilant in Advanced OC (57:08)
• Utility of Immune Checkpoint Inhibition in Advanced OC (1:14:12)

NCPD information and select publications

Featuring perspectives from Dr Floor J Backes, Dr Brian M Slomovitz and Dr Shannon N Westin, moderated by Dr Westin, including the following topics:

• Introduction (00:00)
• Current Up-Front Chemoimmunotherapeutic Approaches for Advanced Endometrial Cancer (EC) — Dr Backes (1:50)
• Current and Future Role of Anti-PD-1/PD-L1 Antibodies in Combination with Systemic Therapies Beyond Chemotherapy for Advanced EC — Dr Westin (33:15)
• Promising Agents Under Investigation for EC — Dr Slomovitz (1:01:41)

CME information and select publications

Featuring perspectives from Dr Ramez N Eskander, Dr Ursula Matulonis, Dr Kathleen N Moore, Dr Alexander B Olawaiye and Dr David M O'Malley, moderated by Dr Moore, including the following topics:

• Introduction (00:00)
• Current Role of PARP Inhibitors in the Management of Advanced Ovarian Cancer (OC) — Prof Eskander (2:40)
• Strategies Targeting Folate Receptor Alpha in Advanced OC — Dr Matulonis (27:41)
• Other Approved and Promising Investigational Antibody-Drug Conjugates for Advanced OC — Dr Moore (52:12)
• Other Novel Agents and Strategies for Advanced OC — Dr O'Malley (1:14:35)
• Diagnosis and Management of Adverse Events Associated with Common Therapies for Advanced OC — Dr Olawaiye (1:39:39)

CME information and select publications